TCF19

Summary

TCF19 (transcription factor 19, HGNC:11629) is a protein-coding gene on chromosome 6p21.33, encoding Transcription factor 19 (Q9Y242). Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition.

This gene encodes a protein that contains a PHD-type zinc finger domain and likely functions as a transcription factor. The encoded protein plays a role proliferation and apoptosis of pancreatic beta cells. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 6941 — RefSeq curated summary.

At a glance

• GWAS associations: 47
• Clinical variants (ClinVar): 53 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_007109

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:11629
Approved symbol	TCF19
Name	transcription factor 19
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	SC1
Ensembl gene	ENSG00000137310
Ensembl biotype	protein_coding
OMIM	600912
Entrez	6941

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 14 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000376255, ENST00000376257, ENST00000496421, ENST00000542218, ENST00000706778, ENST00000706779, ENST00000706780, ENST00000706781, ENST00000706782, ENST00000706783, ENST00000706784, ENST00000706785, ENST00000706786, ENST00000706787, ENST00000706788, ENST00000866485, ENST00000971426, ENST00000971427

RefSeq mRNA: 3 — MANE Select: NM_007109 NM_001077511, NM_001318908, NM_007109

CCDS: CCDS43446

Canonical transcript exons

ENST00000376257 — 4 exons

Exon	Start	End
ENSE00001826145	31158589	31158722
ENSE00002202203	31161447	31162005
ENSE00003996944	31158897	31159707
ENSE00003996951	31162477	31164215

Expression profiles

Bgee: expression breadth ubiquitous, 133 present calls, max score 86.66.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.1033 / max 155.1186, expressed in 1639 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
66867	15.1033	1639

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.66	gold quality
ventricular zone	UBERON:0003053	85.95	gold quality
lymph node	UBERON:0000029	83.85	gold quality
ganglionic eminence	UBERON:0004023	82.99	gold quality
mucosa of transverse colon	UBERON:0004991	82.79	gold quality
bone marrow	UBERON:0002371	82.46	gold quality
vermiform appendix	UBERON:0001154	81.70	gold quality
stromal cell of endometrium	CL:0002255	81.32	gold quality
esophagus mucosa	UBERON:0002469	80.91	gold quality
bone marrow cell	CL:0002092	80.74	gold quality
granulocyte	CL:0000094	79.07	gold quality
lower esophagus mucosa	UBERON:0035834	78.75	gold quality
rectum	UBERON:0001052	78.49	gold quality
skin of leg	UBERON:0001511	77.77	gold quality
zone of skin	UBERON:0000014	77.68	gold quality
skin of abdomen	UBERON:0001416	77.54	gold quality
spleen	UBERON:0002106	77.45	gold quality
apex of heart	UBERON:0002098	77.33	gold quality
smooth muscle tissue	UBERON:0001135	76.99	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.89	gold quality
ectocervix	UBERON:0012249	76.72	gold quality
descending thoracic aorta	UBERON:0002345	76.39	gold quality
cerebellar hemisphere	UBERON:0002245	76.37	gold quality
endometrium	UBERON:0001295	76.34	gold quality
cerebellum	UBERON:0002037	76.34	gold quality
cerebellar cortex	UBERON:0002129	76.33	gold quality
vagina	UBERON:0000996	76.31	gold quality
right hemisphere of cerebellum	UBERON:0014890	75.99	gold quality
calcaneal tendon	UBERON:0003701	75.93	gold quality
esophagus	UBERON:0001043	75.80	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.60

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
CCNE1	Repression

miRNA regulators (miRDB)

55 targeting TCF19, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-6793-5P	99.97	65.95	758
HSA-MIR-4267	99.96	66.53	2368
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-6875-3P	99.82	70.26	2983
HSA-MIR-4755-5P	99.71	70.34	2716
HSA-MIR-5006-3P	99.71	70.26	2728
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-5197-5P	99.64	69.08	1494
HSA-MIR-7150	99.62	66.80	1322
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4480	99.42	66.02	735
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-135A-5P	99.36	71.85	1601
HSA-MIR-135B-5P	99.36	71.63	1613
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-3160-5P	99.28	69.07	1938
HSA-MIR-6852-5P	99.17	66.69	2073
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-7113-3P	98.75	65.71	1120
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-4680-3P	98.64	68.60	2093
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6811-3P	98.62	66.54	944

Literature-anchored findings (GeneRIF, showing 12)

• A linkage disequilibrium analysis established TCF19, POU5F1, CCHCR1 and PSORS1C1 as potential causal genes for the type 1 diabetes. (PMID:21076979)
• Genome association studies identified TCF19 as a new risk-associated loci for chronic hepatitis B on the HLA region of chromosome 6. (PMID:23760081)
• Data shows increased apoptosis and susceptibility to endoplasmic reticulum (ER) stress after Tcf19 knockdown. (PMID:23860123)
• Knockdown of Tcf19 reduces proliferation and increases apoptosis. Tcf19 is found in pancreatic islets in mouse and human. (PMID:23860123)
• Data suggest TCF19 interacts with histone 3 lysine 4 trimethylation through its plant homeodomain finger; TCF19 expression appears to regulate gluconeogenesis in hepatocytes; TCF19 interacts with CHD4 causing NuRD complex recruitment to gene promoters of enzymes involved in gluconeogenesis. (TCF19 = transcription factor 19; CHD4 = chromodomain helicase DNA binding protein 4; NuRD = nucleosome-remodeling-deacetylase) (PMID:29042441)
• AKT/FOXO1 signaling is essential for TCF19 influence on hepatocellular carcinoma progression (PMID:30509085)
• TCF19 Promotes Cell Proliferation through Binding to the Histone H3K4me3 Mark. (PMID:31746185)
• TCF19 aggravates the malignant progression of colorectal cancer by negatively regulating WWC1. (PMID:32016966)
• Genetic variants associated with expression of TCF19 contribute to the risk of head and neck cancer in Chinese population. (PMID:34085947)
• TCF19 and p53 regulate transcription of TIGAR and SCO2 in HCC for mitochondrial energy metabolism and stress adaptation. (PMID:34369624)
• Exon and intron sharing in opposite direction-an undocumented phenomenon in human genome-between Pou5f1 and Tcf19 genes. (PMID:34610795)
• Multidimensional data analysis revealed thyroiditis-associated TCF19 SNP rs2073724 as a highly ranked protective variant in thyroid cancer. (PMID:38579171)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	tcf19l	ENSDARG00000040036
mus_musculus	Tcf19	ENSMUSG00000050410
rattus_norvegicus	Tcf19	ENSRNOG00000058288
caenorhabditis_elegans		WBGENE00007227

Protein

Protein identifiers

Transcription factor 19 — Q9Y242 (reviewed: Q9Y242)

Alternative names: Transcription factor SC1

All UniProt accessions (6): Q9Y242, A0A1U9X8M7, A0A9L9PXI0, A0A9L9PXV2, A0A9L9PXX5, H0YFN0

UniProt curated annotations — full annotation on UniProt →

Function. Potential transcription factor that may play a role in the regulation of genes involved in cell cycle G1/S transition. May bind to regulatory elements of genes, including the promoter of the transcription factor FOXO1.

Subcellular location. Nucleus.

RefSeq proteins (3): NP_001070979, NP_001305837, NP_009040* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000253	FHA_dom	Domain
IPR001965	Znf_PHD	Domain
IPR008984	SMAD_FHA_dom_sf	Homologous_superfamily
IPR011011	Znf_FYVE_PHD	Homologous_superfamily
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR019786	Zinc_finger_PHD-type_CS	Conserved_site
IPR019787	Znf_PHD-finger	Domain
IPR039095	TCF19_PHD	Domain
IPR042803	TCF19	Family

Pfam: PF00498, PF00628

UniProt features (20 total): binding site 8, sequence conflict 4, sequence variant 3, chain 1, domain 1, modified residue 1, zinc finger region 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y242-F1	63.17	0.13

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 336; 339; 296; 298; 310; 313; 318; 321

Post-translational modifications (1): 78

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9940951	Interaction of NuRD complexes with transcription factors

MSigDB gene sets: 0 (showing top):

GO Biological Process (1): regulation of gene expression (GO:0010468)

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
NuRD complex assembly	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
gene expression	1
regulation of macromolecule biosynthetic process	1
transition metal ion binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

1670 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TCF19	CCHCR1	Q8TD31	785
TCF19	HLA-C	P04222	757
TCF19	POU5F1	P31359	706
TCF19	PRMT5	O14744	693
TCF19	CDSN	Q15517	646
TCF19	PSORS1C1	Q9UIG5	594
TCF19	C6orf15	Q6UXA7	579
TCF19	EHMT2	Q96KQ7	561
TCF19	RNF39	Q9H2S5	560
TCF19	INTS10	Q9NVR2	557
TCF19	GNL1	P36915	508
TCF19	PSORS1C2	Q9UIG4	507
TCF19	FGD2	Q7Z6J4	489
TCF19	MUC22	E2RYF6	476
TCF19	ABCF1	Q8NE71	474

IntAct

57 interactions, top by confidence:

A	B	Type	Score
GOLGA2	TCF19	psi-mi:“MI:0915”(physical association)	0.740
TCF19	E2F6	psi-mi:“MI:0914”(association)	0.620
TCF19	E2F6	psi-mi:“MI:0915”(physical association)	0.620
TCF19	ZGPAT	psi-mi:“MI:0915”(physical association)	0.560
TCF19	DDIT4L	psi-mi:“MI:0915”(physical association)	0.560
BLZF1	TCF19	psi-mi:“MI:0915”(physical association)	0.560
ZGPAT	TCF19	psi-mi:“MI:0915”(physical association)	0.560
DDIT4L	TCF19	psi-mi:“MI:0915”(physical association)	0.560
HSF2BP	TCF19	psi-mi:“MI:0915”(physical association)	0.560
CEP76	TCF19	psi-mi:“MI:0915”(physical association)	0.560
NOXA1	TCF19	psi-mi:“MI:0915”(physical association)	0.560
PFDN5	TCF19	psi-mi:“MI:0915”(physical association)	0.560
PRKAB2	TCF19	psi-mi:“MI:0915”(physical association)	0.560
RHOH	TCF19	psi-mi:“MI:0915”(physical association)	0.560
TRIB3	TCF19	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	TCF19	psi-mi:“MI:0915”(physical association)	0.560
PDLIM7	TCF19	psi-mi:“MI:0915”(physical association)	0.560
NFKBID	TCF19	psi-mi:“MI:0915”(physical association)	0.560
ZNF474	TCF19	psi-mi:“MI:0915”(physical association)	0.560
DNAJA3	TCF19	psi-mi:“MI:0915”(physical association)	0.370
TCF19	LZTR1	psi-mi:“MI:0915”(physical association)	0.370
TCF19	UBE3A	psi-mi:“MI:0915”(physical association)	0.370
TCF19	HSF2BP	psi-mi:“MI:0915”(physical association)	0.000
TCF19	BLZF1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (47): TCF19 (Two-hybrid), DNAJA3 (Two-hybrid), TCF19 (Reconstituted Complex), TCF19 (Two-hybrid), E2F6 (Affinity Capture-MS), MBD3 (Affinity Capture-MS), MTA3 (Affinity Capture-MS), MTA2 (Affinity Capture-MS), LIN9 (Affinity Capture-MS), GATAD2B (Affinity Capture-MS), MTA1 (Affinity Capture-MS), HIST3H3 (Reconstituted Complex), HIST4H4 (Reconstituted Complex), HIST3H3 (Affinity Capture-Western), HIST4H4 (Affinity Capture-Western)

ESM2 similar proteins: A5D7F8, A5H447, A5WW08, A6NIX2, E1BKA3, O54967, O70142, O97581, P50481, Q04584, Q07912, Q0VA45, Q14202, Q15654, Q15942, Q17R13, Q1JQB5, Q3SX26, Q3T0C8, Q5JV73, Q5REN1, Q5RF77, Q5TM48, Q5U2X5, Q5U2Z2, Q62523, Q63767, Q6ZQM0, Q71FD7, Q7TQJ8, Q7TSG2, Q7YR48, Q810L3, Q86XL3, Q8BMC3, Q8CIN9, Q8K0W3, Q8R1G6, Q8WUP2, Q91XC0

Diamond homologs: A2Y0Q2, B8AMA8, B8B8I3, B8BJV8, E6ZGB4, F4JGB7, F4JL28, O75151, P0CF52, P0CH95, P26358, Q08D35, Q12830, Q23541, Q2R837, Q3UHR0, Q3UWM4, Q54DV0, Q5EA28, Q5RHD1, Q5TM48, Q6BER5, Q6P949, Q6ZMT4, Q75IR6, Q7YR48, Q80TJ7, Q84TV4, Q8H383, Q8LA16, Q8S8M9, Q92576, Q9CWW7, Q9FEN9, Q9P0U4, Q9P281, Q9TSV4, Q9UPP1, Q9UT79, Q9W0T1

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	43
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1414 predictions. Top by Δscore:

Variant	Effect	Δscore
6:31159708:G:GA	donor_loss	1.0000
6:31161419:T:G	acceptor_gain	1.0000
6:31161420:ATTT:A	acceptor_gain	1.0000
6:31164864:CCAC:C	acceptor_gain	1.0000
6:31164865:CAC:C	acceptor_gain	1.0000
6:31164865:CACC:C	acceptor_gain	1.0000
6:31164867:CCT:C	acceptor_loss	1.0000
6:31164868:C:CC	acceptor_gain	1.0000
6:31164874:G:C	acceptor_gain	1.0000
6:31165123:CTCA:C	donor_loss	1.0000
6:31165124:TCACA:T	donor_loss	1.0000
6:31165125:CACAT:C	donor_loss	1.0000
6:31165126:A:AC	donor_gain	1.0000
6:31165126:ACAT:A	donor_gain	1.0000
6:31165126:ACATC:A	donor_gain	1.0000
6:31165127:C:CG	donor_gain	1.0000
6:31165127:CAT:C	donor_gain	1.0000
6:31165127:CATC:C	donor_gain	1.0000
6:31165127:CATCC:C	donor_gain	1.0000
6:31165129:T:TA	donor_gain	1.0000
6:31165282:CATAT:C	acceptor_gain	1.0000
6:31165565:CCTTA:C	donor_loss	1.0000
6:31165566:CTTAC:C	donor_loss	1.0000
6:31165567:TTA:T	donor_loss	1.0000
6:31165568:TA:T	donor_loss	1.0000
6:31165569:A:T	donor_loss	1.0000
6:31165569:ACCT:A	donor_gain	1.0000
6:31165570:C:A	donor_loss	1.0000
6:31165570:CCTC:C	donor_gain	1.0000
6:31165572:T:TA	donor_gain	1.0000

AlphaMissense

2221 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:31159530:T:C	F21L	0.992
6:31159532:C:A	F21L	0.992
6:31159532:C:G	F21L	0.992
6:31161599:T:C	F131L	0.991
6:31161601:T:A	F131L	0.991
6:31161601:T:G	F131L	0.991
6:31159531:T:C	F21S	0.990
6:31161495:T:C	L96S	0.990
6:31161569:T:C	F121L	0.990
6:31161571:C:A	F121L	0.990
6:31161571:C:G	F121L	0.990
6:31159641:G:C	A58P	0.989
6:31159642:C:A	A58D	0.989
6:31161570:T:C	F121S	0.989
6:31161732:T:C	I175T	0.989
6:31159560:T:G	Y31D	0.988
6:31159483:T:C	F5S	0.985
6:31161456:T:A	V83D	0.985
6:31161600:T:C	F131S	0.985
6:31162628:T:C	F317L	0.984
6:31162630:C:A	F317L	0.984
6:31162630:C:G	F317L	0.984
6:31159654:C:A	A62D	0.983
6:31162607:T:C	C310R	0.983
6:31159648:T:C	L60P	0.982
6:31162600:G:C	W307C	0.982
6:31162600:G:T	W307C	0.982
6:31159567:T:C	L33S	0.981
6:31161459:A:T	N84I	0.981
6:31162607:T:A	C310S	0.981

dbSNP variants (sampled 300 via entrez): RS1000226564 (6:31158753 G>C), RS1000507363 (6:31158499 C>G,T), RS1000615578 (6:31164140 A>G), RS1000654068 (6:31158477 T>A,C), RS1001481045 (6:31157529 G>A), RS1001787820 (6:31160126 A>G), RS1001853689 (6:31163746 T>A,C), RS1002114329 (6:31160484 G>A), RS1003382497 (6:31162421 C>G,T), RS1003981245 (6:31161987 C>T), RS1004012272 (6:31161584 G>T), RS1004406067 (6:31159314 T>C), RS1004713163 (6:31158199 A>G), RS1004742618 (6:31157998 C>G), RS1005007835 (6:31159761 A>C)

Disease associations

OMIM: gene MIM:600912 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): sensorineural hearing loss disorder (MONDO:0020678)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000407	Sensorineural hearing impairment

GWAS associations

47 associations (top):

Study	Trait	p-value
GCST000984_6	Idiopathic membranous nephropathy	3.000000e-58
GCST001239_1	Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS-TEN)	2.000000e-08
GCST002068_6	Chronic hepatitis B infection	1.000000e-18
GCST002140_3	Multiple myeloma	1.000000e-10
GCST002352_17	Type 2 diabetes	4.000000e-09
GCST002742_2	Marginal zone lymphoma	2.000000e-09
GCST002879_12	Chronic hepatitis B infection	3.000000e-07
GCST003542_141	Night sleep phenotypes	5.000000e-06
GCST004131_25	Inflammatory bowel disease	2.000000e-31
GCST004133_79	Ulcerative colitis	5.000000e-65
GCST004521_103	Autism spectrum disorder or schizophrenia	2.000000e-08
GCST004521_107	Autism spectrum disorder or schizophrenia	2.000000e-08
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_124	Autism spectrum disorder or schizophrenia	3.000000e-12
GCST004521_126	Autism spectrum disorder or schizophrenia	2.000000e-10
GCST004521_132	Autism spectrum disorder or schizophrenia	2.000000e-09
GCST004521_16	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_167	Autism spectrum disorder or schizophrenia	4.000000e-16
GCST004521_19	Autism spectrum disorder or schizophrenia	2.000000e-12
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_210	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_213	Autism spectrum disorder or schizophrenia	5.000000e-13
GCST004521_229	Autism spectrum disorder or schizophrenia	4.000000e-11
GCST004521_257	Autism spectrum disorder or schizophrenia	6.000000e-10
GCST004521_265	Autism spectrum disorder or schizophrenia	7.000000e-14
GCST004521_27	Autism spectrum disorder or schizophrenia	1.000000e-09
GCST004521_282	Autism spectrum disorder or schizophrenia	5.000000e-09
GCST004521_295	Autism spectrum disorder or schizophrenia	6.000000e-18

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008002	physical activity measurement
EFO:0007789	BMI-adjusted waist circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

1 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs2073724	Toxicity	3	nevirapine	HIV infectious disease

PharmGKB variants

2 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs2073724	TCF19	3	3.25	1	nevirapine
rs3130931	POU5F1, TCF19	3	0.00	1	allopurinol

CTD chemical–gene interactions

78 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression	7
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Cyclosporine	decreases expression	3
bisphenol A	affects expression, decreases expression	2
cobaltous chloride	decreases expression, increases expression	2
Benzo(a)pyrene	affects methylation, increases expression	2
Estradiol	increases expression	2
Aflatoxin B1	affects expression, increases expression	2
Cadmium Chloride	decreases expression	2
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
FR900359	decreases phosphorylation	1
methylmercuric chloride	decreases expression	1
lasiocarpine	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
sulforaphane	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
zinc chromate	increases abundance, decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	increases expression, affects cotreatment	1
beta-glycerophosphoric acid	affects cotreatment, decreases expression	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
CGP 52608	affects binding, increases reaction	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	decreases expression, increases response to substance	1
jinfukang	increases expression	1

Cellosaurus cell lines

5 cell lines: 3 embryonic stem cell, 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A7C2	SEES3-1V human TCF19, clone1	Embryonic stem cell	Male
CVCL_A7C3	SEES3-1V human TCF19, clone2	Embryonic stem cell	Male
CVCL_A7C4	SEES3-1V human TCF19, clone3	Embryonic stem cell	Male
CVCL_TR80	HAP1 TCF19 (-) 1	Cancer cell line	Male
CVCL_XU10	HAP1 TCF19 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

89 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01655212	PHASE3	TERMINATED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
NCT02005822	PHASE3	COMPLETED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
NCT03374514	PHASE3	UNKNOWN	Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery
NCT02497690	PHASE2	COMPLETED	Effectiveness of Therapy Via Telemedicine Following Cochlear Implants
NCT03107871	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05061758	PHASE2	WITHDRAWN	A Trial of LY3056480 in Patients With SNLH
NCT07364747	PHASE2	RECRUITING	Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT02693704	PHASE2/PHASE3	COMPLETED	Evaluation of a Binaural Spatialization Method for Hearing Aids
NCT02882477	PHASE2/PHASE3	UNKNOWN	Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
NCT01267994	PHASE1/PHASE2	COMPLETED	A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
NCT01902914	PHASE1/PHASE2	UNKNOWN	Effectiveness of P02 Digital Hearing Aids
NCT02038972	PHASE1/PHASE2	COMPLETED	Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
NCT02616172	PHASE1/PHASE2	SUSPENDED	Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss
NCT03616223	PHASE1/PHASE2	COMPLETED	FX-322 in Sensorineural Hearing Loss
NCT04129775	PHASE1/PHASE2	COMPLETED	OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04462198	PHASE1/PHASE2	COMPLETED	Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
NCT07032038	PHASE1/PHASE2	NOT_YET_RECRUITING	First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT06025097	EARLY_PHASE1	COMPLETED	Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
NCT06707389	EARLY_PHASE1	NOT_YET_RECRUITING	Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
NCT07472023	EARLY_PHASE1	ENROLLING_BY_INVITATION	Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
NCT00023036	Not specified	COMPLETED	Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
NCT00023049	Not specified	COMPLETED	Genetic Analysis of Hereditary Disorders of Hearing and Balance
NCT00261768	Not specified	COMPLETED	Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial
NCT00589511	Not specified	COMPLETED	Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study
NCT00678899	Not specified	COMPLETED	Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System
NCT00787189	Not specified	COMPLETED	Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals
NCT01184248	Not specified	COMPLETED	The Effect of Sound Stimulation on Pure-tone Hearing Threshold
NCT01434446	Not specified	COMPLETED	The Effect of Sound Stimulation on Hearing Ability
NCT01749592	Not specified	COMPLETED	Single-sided Deafness and Cochlear Implants
NCT01781039	Not specified	COMPLETED	Investigation of Anatomical Correlates of Speech Discrimination
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02093806	Not specified	UNKNOWN	Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery
NCT02252601	Not specified	UNKNOWN	Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis
NCT02584361	Not specified	UNKNOWN	Cochlear Implant and Vestibular Function.
NCT02638883	Not specified	COMPLETED	Implantation of the Cochlear™ Nucleus® Hybrid S Round Window (S-RW) in Adults
NCT02689349	Not specified	COMPLETED	Esteem New Subject Enrollment Post Approval Study
NCT02698787	Not specified	COMPLETED	Fundamental Asynchronous Stimulus Timing Sound Coding Study
NCT02798783	Not specified	COMPLETED	Enlarged Vestibular Aqueduct Registry